Amylin: The Pancreatic Hormone Emerging as a Powerful Obesity and Diabetes Treatment | Research

The takeaway

Long-acting amylin analogs like cagrilintide produce substantial weight loss, and combining them with GLP-1 drugs achieves synergistic effects exceeding 15% body weight reduction.

>15% weight loss
Amylin analog + GLP-1 RA combination therapy for diabesity in clinical studies

What the researchers found

Cagrilintide combined with GLP-1 receptor agonists achieves synergistic weight loss exceeding 15%, positioning amylin analogs as key players in diabesity treatment.

Why it matters

Obesity and diabetes together (diabesity) are a growing global epidemic. Amylin analogs offer a new hormonal pathway to complement GLP-1 drugs, potentially achieving weight loss and glucose control that neither achieves alone.

How the study worked

Narrative review of preclinical and clinical studies on amylin physiology and analog development over the past five years.

What this study cannot tell us

Review article without new primary data. Long-term safety and durability of amylin analog effects still need confirmation from large phase 3 trials.

How to read the evidence

Narrative review covering a mix of preclinical data and early clinical trials; cagrilintide results are promising but from smaller studies.

When this study was published

Published in 2026, reviewing advances from 2021–2026.

The bigger picture

The combination of amylin and GLP-1 pathways represents the next frontier in metabolic medicine, moving beyond single-hormone approaches toward multi-target therapies for obesity and diabetes.

Questions still open

Will cagrilintide plus semaglutide (CagriSema) maintain its weight loss advantage in large phase 3 trials?
What is the long-term cardiovascular safety profile of amylin-GLP-1 combinations?
Can amylin analogs benefit patients who have plateaued on GLP-1 monotherapy?

Common questions

What is amylin and how is it different from GLP-1?

Amylin is a hormone co-released with insulin from the pancreas. While GLP-1 drugs mimic a gut hormone to boost insulin and reduce appetite, amylin works through different brain pathways to promote fullness and slow stomach emptying—combining both covers more biological pathways.

Is cagrilintide available yet?

Cagrilintide is in advanced clinical trials, often combined with semaglutide as CagriSema. It is not yet FDA-approved but may become available pending successful phase 3 results.

Read the original research

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.

Journal of obesity & metabolic syndrome, 35(1), 38-48

View on PubMed ↗Publisher’s paper ↗

Citation

Chung, Chae Won; Kim, Jaetaek. (2026). Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.. Journal of obesity & metabolic syndrome, 35(1), 38-48. https://doi.org/10.7570/jomes25085